Service-Tutorial-Lab near Tache MB (52 Result(s))

7% of Canadians have Macular DegenerationBy 2030, over 20% of Canadians will have Macular Degeneration1 in 9 of those over 65 have reduced visionResearch studies tell us that individuals who are legally blind would give up 60% of their remaining lifespan to see again1 in 4 of those over 80 have a vision impairmentEye Canada 2009 Helping You See BetterFocusing on Low Vision Care in Canada 2-1200 Waverley Street, Winnipeg, Manitob,a Canada

We are North Forge Technology Exchange – a hybrid incubator/accelerator and the innovation partner for the Province of Manitoba. We fuel Manitoba’s innovation economy providing entrepreneurs with award-winning mentors, rockstar subject matter experts, and a new four-stage Founders Program. We have helped over 60 companies access over 180 million dollars in financing and created hundreds of jobs. Armed with Canada’s largest non-profit fabrication lab, we operate out of 27,000 square feet across Innovation Drive and Innovation Alley in Winnipeg, Canada.

Saving Lives Through Early Disease DiagnosisMiraculins is an emerging biotechnology company committed to extending life, reducing suffering and lowering healthcare costs. Through our leadership in the development and commercialization of diagnostic tests, we strive to improve the overall diagnosis and treatment of patients by enhancing the information available to physicians.The Miraculins AdvantageProducts & ProgramsMiraculins is dedicated to the development and commercialization of diagnostic tests and risk assessment technologies for diseases and conditions that are lacking highly sensitive and specific tests.

Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet needAbout MedicureMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.HistoryMedicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicurés business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.TodayMedicurés core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT.

What makes Undefeated CrossFit different? FIND OUTJoin Our PackCheck out a free trial class to see what the hype is about! GET STARTEDWe're All In This TogetherOur documentary follows five unique individuals who train to compete in a CrossFit competition. WATCH NOWOur 'Workout of the Day'Challenging, constantly varied, and scaled to your ability. GET FIT!Forging Elite FitnessWhat makes Undefeated CrossFit different?Join Our PackCheck out a free trial class to see what the hype is about!We're All In This TogetherOur documentary follows five unique individuals who train to compete in a CrossFit competition.Our 'Workout of the Day'Challenging, constantly varied, and scaled to your ability.CrossFit CommunityEquipment and Signage Provided BySocial Media